For laboratory research use only. Not for human or veterinary use. Read our research-use policy

GLP-1 research

Retatrutide research peptide

A synthetic peptide that agonises the glucagon, GIP and GLP-1 receptors (development code LY3437943).

9 sizes · from $17.99 · 3 in stock · flat $24.95 US shipping per order

Sizes, prices and availability

Retatrutide sizes and prices
SizeSKUStated purityBatch COAPriceAvailability
5 mg RT5 Not yet provided Not yet provided $17.99 Out of stock
10 mg SKUR3TAVER10 99%+ (supplier) Not yet provided $25.99 In stock
15 mg RT15 Not yet provided Not yet provided $31.99 Out of stock
20 mg RT20 Not yet provided Not yet provided $38.99 Out of stock
30 mg RT30 Not yet provided Not yet provided $53.99 In stock
40 mg RT40 Not yet provided Not yet provided $62.99 Out of stock
50 mg RT50 Not yet provided Not yet provided $77.99 Out of stock
60 mg SKUR3TAVER60 99%+ (supplier) Not yet provided $91.99 In stock
100 mg RT100 Not yet provided Not yet provided $108.99 Out of stock

Blend vials containing Retatrutide

Blend vials containing Retatrutide
SizeSKUStated purityBatch COAPriceAvailability
Retatrutide 5mg + Cagrilintide 5mg RC10 Not yet provided Not yet provided $25.99 Out of stock

Prices and stock are checked at build time and refreshed live in your browser. Orders are US only for a flat $24.95 shipping fee. Shipping details

About Retatrutide

Retatrutide (development code LY3437943) is a synthetic peptide that acts as an agonist at three receptors: the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). The discovery paper describes balanced GCGR and GLP-1R activity in vitro with comparatively more GIPR activity.

Tirzepatide acts on GIPR and GLP-1R only, so the practical structural and pharmacological difference between the two is the added glucagon-receptor activity of retatrutide. Researchers compare them for that reason; the comparison pages in our library cover the receptor targets in more detail as they are published.

What the published literature covers

  • The discovery and early-clinical paper (Coskun et al., 2022) reports that in obese mice the body-weight reduction was augmented when GCGR-mediated increases in energy expenditure were added to GIPR- and GLP-1R-driven reductions in calorie intake.
  • The same paper reports a pharmacokinetic profile that supported once-weekly administration in a phase 1 single-ascending-dose study.
  • Phase 2 clinical results have been published in the New England Journal of Medicine (obesity) and Nature Medicine (liver fat); phase 3 reports have followed in 2026.

Vial arithmetic for Retatrutide

Work out the concentration, syringe units per draw and draws per vial for any Retatrutide vial size with our Retatrutide reconstitution calculator, or the general peptide reconstitution calculator. To turn a volume into syringe units, use the syringe units converter or, for the blend vials, the peptide blend calculator. These tools do arithmetic only; they do not suggest any amount.

FAQ

Which receptors does retatrutide act on?

Retatrutide is described as an agonist at three receptors: the glucagon receptor, the GIP receptor and the GLP-1 receptor (Coskun et al., 2022).

How does retatrutide differ from tirzepatide?

Tirzepatide is a dual GIP and GLP-1 receptor agonist. Retatrutide adds agonism at the glucagon receptor, which is why it is called a triple agonist.

What sizes of Retatrutide does Covalume list?

Covalume lists Retatrutide in 9 sizes: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 100 mg. Each size shows its price and live stock status in the variants table on this page.

How is the purity of Retatrutide documented?

Each listing shows the purity the supplier states, labelled (supplier), and the batch Certificate of Analysis field reads "Not yet provided" until a batch-specific document is on file. Our guide to reading a Certificate of Analysis explains what HPLC and mass-spectrometry results show.

References

  1. Coskun T, Urva S, Roell WC, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab 34:1234-1247.e9. PubMed 35985340 · DOI
  2. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med 389:514-526. PubMed 37366315 · DOI
  3. Sanyal AJ, Kaplan LM, Frias JP, et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med 30:2037-2048. PubMed 38858523 · DOI

Identity values are from PubChem and the cited papers; for linear peptides the mass was also checked against the sequence. Last updated 2026-11-18.

Related research peptides

From the research library